Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

As more Asia biotechs turn to regenerative medicine to address disorders without a cure, Medipost Inc. is continuing global ...

Evolus faces sector instability but shows strong growth potential. Learn why EOLS stock remains a “Buy” despite challenges, ...

After striking out last session, a plan for Illinois to import less-expensive prescription drugs from Canada for health plans ...

AbCellera is expanding its collaboration with pharmaceutical company AbbVie to include the discovery of T-cell engagers in oncology. The new agreement will see the Canadian developer of antibody ...

Under the terms of the agreement, AbCellera will lead discovery activities and AbbVie has the right to develop and commercialize therapeutic antibodies resulting from the collaboration. AbCellera will ...

A Representative from North Carolina has disclosed the sale of up to $100,000 in stock from Pembina Pipeline Corporation.

In an SEC filing, AbbVie ABBV has disclosed that it is lowering its previously issued guidance for 2024 adjusted earnings per ...

AbbVie lowered its 2024 adjusted profit forecast on Monday as the drugmaker incurred $1.6 billion in acquisition expenses ...

Boltwood Capital Management decreased its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 1.4% in the 4th quarter, ...

Corporate borrowing surged to a record in 2024, up over a third from a year earlier as companies like AbbVie and Cisco looked ...

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable ...